Quick answers
- Is CVE-2026-79316 exploited in the wild?
- No. Junglewise Threat Intelligence has no report of CVE-2026-79316 being exploited in the wild.
- How severe is CVE-2026-79316?
- High severity, with a CVSS score of 7.6, published 21 September 2026.
- Which products and versions are affected?
- Vaxilu X-Ui 0.3.2.
- Is there a fix for CVE-2026-79316?
- No fixed version is recorded yet. Check the vendor's advisory in the references below. If you run it, Junglewise drafts a mitigation that fits your setup and applies it once you approve, with senior security engineers behind it.
- How is CVE-2026-79316 attacked?
- It is attacked over the network.
- Am I affected by CVE-2026-79316?
- Check whether you run Vaxilu X-Ui at an affected version. Junglewise does that check for you around the clock: connect your code, cloud and domains, and it matches new vulnerabilities like this one against what you actually run and tells you when one reaches you.
Technical details
The vulnerability stems from improper access control (CWE-284) combined with unsafe configuration handling. An authenticated panel user can edit the Xray configuration template in settings (which performs only JSON syntax validation, not security constraints) and trigger a panel restart; the template is then applied verbatim to regenerate the runtime configuration, causing the management gRPC interface to bind to a non-loopback address. An attacker with valid panel credentials can exploit this without administrator privileges, requiring only a restart event to activate the malicious configuration.
Affected products
- vaxilu x-ui 0.3.2
Timeline
- 2026-09-21: disclosed
- 2026-08-04: other: Report date